A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700
Recruiting
In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and la... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Arizona Neuroscience Research, Merz Investigational Site #0010521, Phoenix, Arizona
Conditions: Episodic Migraine
Register for Updates
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
NCT06843720
Recruiting
To learn about the attitudes toward implementing self-collection among healthcare providers and staff, participants, and other stakeholders; and to inform the development of patient education and provider training materials to aid in the implementation of self-collection in clinical settings.
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
08/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: HR-HPV Testing
Register for Updates
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713
Recruiting
In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and las... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Arizona Neuroscience Research, Merz Investigational Site #0010521, Phoenix, Arizona
Conditions: Chronic Migraine
Register for Updates
Study of Mycobacterial Infections
NCT00018044
Recruiting
This study will examine the symptoms, course of disease and treatment of non-tuberculous mycobacterial (NTM) infections, as well as the genetics involved in these infections. Patients with NTM have recurrent lung infections and sometimes infections of the skin and other organs as well. They may also have curvature of the spine, barrel chest, and heart valve weakness. The study will compare the features of NTM with those of Job syndrome and cystic fibrosis, other diseases involving recurrent infe... Read More
Gender:
ALL
Ages:
100 years and below
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Mycobacterium Infections
Register for Updates
Study of Inborn Errors of Cholesterol Synthesis and Related Disorders
NCT00046202
Recruiting
This study will investigate the cause and medical problems associated with a group of genetic disorders known as inborn errors of cholesterol synthesis, in which the body does not produce cholesterol. People with this disorder may have birth defects and learning and behavioral problems. People with an inborn error of cholesterol synthesis and related disorders, including Smith-Lemli-Opitz syndrome, lathosterolosis, desmosterolosis, X-linked dominant chondrodysplasia, CHILD syndrome, Greenberg d... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lysosomal Storage Disease, Cholesterol Metabolism
Register for Updates
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
NCT02741440
Recruiting
Background: Spinocerebellar ataxia type 7 (SCA7) is a disease in which people have problems with coordination, balance, speech and vision. It is caused by a change in the ATXN7 gene. A mutation in this ATXN7 gene causes changes in eye cells, which can lead to vision loss. There is no cure for SCA7 but researchers are looking for possible treatments. Researchers need more information about SCA7. They want to collect vision and neurology related data from people with SCA7. They want to learn how... Read More
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Spinocerebellar Ataxia
Register for Updates
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT07096674
Recruiting
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/13/2025
Locations: Site Number 1, Huntersville, North Carolina
Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Register for Updates
Genomic Services Research Program
NCT02595957
Recruiting
Background: Genes are the instructions a person s body uses to function. Genome sequencing reads through all of a person s genes. Everyone has many gene variants, and most do not cause disease. Some gene variants called secondary findings may be important for a person s health even if they are not related to the reason why a person had genome sequencing done. Researchers want to learn more about what it means to have a secondary finding. Objectives: To learn about how gene variants may affect... Read More
Gender:
ALL
Ages:
Between 1 month and 105 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Colon Cancer, Breast Cancer
Register for Updates
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235
Recruiting
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/13/2025
Locations: Cahaba Dermatology & Skin Health Center ( Site 0012), Birmingham, Alabama +20 locations
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555
Recruiting
The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/13/2025
Locations: Cancer and Blood Specialty clinic, Long Beach, California +183 locations
Conditions: Melanoma
Register for Updates
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
NCT00001281
Recruiting
We are studying virologic and/or immunologic parameters of HIV infection and other infectious or non-infectious immune deficiency diseases in order to better understand the pathogenesis of HIV. Because of the lack of an adequate animal model it is generally necessary to utilize human peripheral blood cells for studying aspects of either in vivo or in vitro HIV infection. We wish to be able to continue to elucidate many pathogenic aspects of HIV infection in relation to other infectious or non-in... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/13/2025
Locations: Washington Hospital Center, Washington, District of Columbia +1 locations
Conditions: HIV, Immunodeficiencies, Infectious Diseases
Register for Updates
Targeting Aging With a Ketone Ester for Function in Frailty
NCT06645847
Recruiting
This study aims to find out if a food supplement that contains a naturally occurring substance, ketones, can help to improve strength and general wellness in adults at, or over the age of 65 years who are experiencing a slight decline in their physical function. Participation will involve a screening visit and 4 additional study visits over the course of 20 weeks. After being assessed for eligibility, study participants will be sorted into two groups at random and consume either a ketone or pla... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/13/2025
Locations: Buck Institute for Research on Aging, Novato, California +2 locations
Conditions: Frail Elderly, Aging, Immune Function, Muscle Function
Register for Updates